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Background: Anti-endothelial cell antibodies (AECA) are circulating antibodies that bind
to endothelial antigens and induce endothelial cell damage. AECA have been detected in
patients with collagen vascular disease (CVD) and their presence is associated with
interstitial lung disease (ILD) in cases of CVD. However, the prevalence of AECA in patients
with idiopathic interstitial pneumonias (IIPs) is not known.
Methods: We investigated the prevalence of AECA in patients with IIPs. We also examined
whether the expression of AECA differed among the histologic subgroups usual interstitial
pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), and compared the values
with those of CVD–associated ILD (CVD-ILD). Twenty patients with IIPs and 24 patients with
CVD-ILD were studied. Serum samples were examined for AECA by cellular enzyme-linked
immunosorbent assay (ELISA) using human umbilical vein endothelial cells. Values are
expressed as ELISA ratios (ER).
Results: All sera from patients with idiopathic pulmonary fibrosis (IPF)/UIP were negative
for AECA, whereas 5 out of 10 with idiopathic NSIP, 5 out of 14 with CVD-UIP and 4 out of 10
with CVD-NSIP tested positive (po0.05). ER values were significantly lower in patients with
IPF/UIP than idiopathic NSIP, CVD-UIP or CVD-NSIP (po0.05). Among idiopathic NSIP,
CVD-NSIP and CVD-UIP patients, the ER values did not differ.
Conclusions: Among IIP patients, only those with idiopathic NSIP, not IPF/UIP, tested
positive for AECA. The prevalence of AECA in idiopathic NSIP patients was similar to that in
CVD-ILD patients. These results may provide important information to understand the
distinct pathophysiology of each form of IIPs.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
435 2263; fax: +81 53 435 2354.
.jp (N. Inui).
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Anti-endothelial cell antibodies (AECA) are a heterogeneous
group of antibodies recognizing various antigenic determi-
nants on human endothelial cells. Although their precise
pathogenic role remains unclear, studies in vitro suggest
that AECA bind to endothelial cell membrane antigens
and damage endothelial cell either through antibody-
dependent cell-mediated cytotoxicity or the recruit-
ment of natural killer cells.1–3 AECA also upregulate the
expression of adhesion molecules on endothelial cells and
induce the secretion of cytokines and chemokines, which
cause leukocyte homing, recruitment and adhesion to
endothelial cells.4,5 AECA have been detected in patients
with collagen vascular diseases (CVDs), including systemic
lupus erythematosus (SLE), systemic sclerosis (SSc) and
rheumatoid arthritis (RA), as well as in patients with
systemic vasculitic diseases.6–13 Although the prevalence
of AECA varies among these diseases, it is correlated with
disease activity and the degree of organ damage, and is
regarded as a risk factor for disease relapse in vasculi-
tis.7–12,16
Interstitial lung diseases (ILDs) are a group of diseases
that involve the space between the epithelial and endothe-
lial basement membranes. ILDs have hundreds of etiological
factors, including environmental exposure and drugs. ILDs
are common in patients with CVD and are a major
determinant of their prognosis. Recent studies have shown
a relationship between AECA and ILD in patients with
CVD. In polymyositis and dermatomyositis (PM/DM),
AECA were detected significantly more frequently in
patients with PM/DM associated ILD than in those with PM/
DM only.14,15 In patients with SSc, AECA were found to be
associated with ILD and an indicator of alveolar-capillary
impairment.16
Idiopathic interstitial pneumonias (IIPs) are a category of
diseases of unknown etiology and are recommended to be
further subdivided into clinico-radiologic-pathologic enti-
ties.17 Among IIPs, idiopathic pulmonary fibrosis (IPF), which
has the pathological features of usual interstitial pneumonia
(UIP), and nonspecific interstitial pneumonia (NSIP), are
perhaps the most clinically important and frequently
occurring. It is critical to differentiate between IPF/UIP
and NSIP pathologically, because of differences in survival
and response to corticosteroids.
Interestingly, endothelial cell injury has recently been
shown to occur in a fibrotic process in patients with ILD,
including those with IIPs and CVD–associated ILD (CVD-
ILD).18 Thus, it is suggested that AECA are involved in
endothelial cell injury in certain groups of IIPs because
of a possible pathogenic role. To date, however, there
has been no attempt to examine the prevalence of AECA
in patients with IIPs. In the present study, we aimed
to evaluate the prevalence of AECA directed against
human umbilical vein endothelial cells (HUVEC) in patients
with IIPs. In addition, we examined whether the pre-
valence and levels of AECA differ among the histologic
subgroups of IIPs, and compared the values with those for
CVD-ILD. Finally, we further studied the relationship
between AECA and clinical or serological features to clarify
the clinical significance of these antibodies in patients
with ILD.Materials and methods
Patients and controls
Twenty patients with IIPs and 24 patients with CVD-ILD who
consecutively underwent a surgical lung biopsy between
1998 and 2006 were included in this study. The diagnosis of
IIP was based on clinical, radiographic, and pulmonary
physiological features, according to the ATS/ERS consensus
classification.17 Histological classification of ILDs was per-
formed based on pathologic findings in surgical lung biopsy
specimens according to the current classification.17 The
underlying diseases in patients with CVD-ILD were RA
(n ¼ 6), SSc (n ¼ 5), Sjo¨gren syndrome (n ¼ 6) and PM/DM
(n ¼ 7), all of which fulfilled the diagnostic criteria.19–22
Serum samples were collected at the time of diagnosis,
when none of the patients were under systemic steroid or
immunosuppressive therapy, and stored at 30 1C until this
investigation. Sera from 35 healthy volunteers matched for
age and sex served as controls. The study protocol was
approved by our institutional review board for human
research. Informed consent was given by each patient.
Data collection
Clinical data, including sex, age, smoking history, symptoms
and outcome was obtained from medical records. Pulmonary
function tests and laboratory parameters, including serum
lactate dehydrogenase (LDH), KL-6 and surfactant protein D
(SP-D), were assessed.
Enzyme-linked immunosorbent assay (ELISA) for the
detection of AECA
The ELISA to detect AECA in sera was performed as
described previously,6 with some modifications. In brief,
HUVEC at passage 3 were seeded in a 96-well flat-bottomed
microtiter plate (Nunc, Denmark) at a concentration of
2 104 cells/well and allowed to grow to confluence as a
monolayer for 2–3 days. Cells were fixed with 0.1%
glutaraldehyde for 10min at 4 1C, and nonspecific binding
sites were blocked with phosphate buffered saline (PBS)–bo-
vine serum albumin (BSA, Sigma) for 1 h at 37 1C. After five
washes, 100 mL of serum diluted 1:1000 in PBS–1% BSA was
added to each well in triplicate for 1 h at 37 1C. The wells
were washed 5 times with PBS–1% BSA and incubated with
horseradish peroxidase-conjugated rabbit F(ab0)2 anti-hu-
man IgG (DAKO, Denmark) diluted 1:800 in PBS–1% BSA for
1 h at 37 1C. After five more washes with PBS–1% BSA,
3,30,5,50-tetramethylbenzidine (TMB; DAKO, USA) was added
as a substrate and incubated at room temperature. After
10min, the enzyme reaction was stopped by the addition of
1M H2SO4, and optical density (OD) was measured at 450 nm
using an ELISA reader (BioTek, USA). The results were
expressed as an ELISA ratio (ER) ¼ (SA)/(BA), where S is
the OD of the sample tested, and A and B indicate the OD of
negative and positive controls, respectively. All assays
included at least one positive and one negative control
sample on each plate. As a positive control, a highly positive
serum sample from an SLE patient without lung disease was
used. As described in previous studies, a sample was judged
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of the healthy control group.
Statistic analysis
All values were analyzed using StatView version 4.5 (Abacus
Concept, CA). The Mann–Whitney U-test and ANOVA were
used for the statistical analysis. Correlations between
different parameters were evaluated with Spearman’s rank
correlation coefficient. p values less than 0.05 were
considered significant. All data are expressed as means7SD.
Results
Characteristics of patients
According to the histological findings, 10 of the IIP patients
were classified as having UIP and 10 as having NSIP. In
addition, among patients with NSIP, 2 patients were
classified as having a cellular pattern and 8 patients were
classified as having a fibrosing pattern. Using the same
histological criteria, 14 of the CVD-ILD patients were
categorized as having UIP and 10 as having NSIP. The clinical
features and laboratory parameters are summarized in
Table 1. Males predominated among those with IPF/UIP
(po0.05). Age, smoking history and laboratory findings did
not differ among the four groups. Serum levels of KL6 and
SP-D, useful markers for the diagnosis and activity of
interstitial pneumonia, also did not differ among the groups.
A control group comprising 21 males and 14 females with
a mean age of 54 (range, 21–84) was studied to determineTable 1 Patients’ characteristics.
IIP
IPF/UIP Idio
Patients (n) 10 10
Age (years) 63.278.5 58.
Male 10 (1 0 0) 3
Smoker 10 (1 0 0) 4
FVC (L) 2.770.8 2.
FVC (%) 83.3725.7 74.
PaO2 (mmHg) 76.777.3 78.
LDH (IU/L) 232747 25
IgG (mg/dL) 15687371 155
KL-6 (U/mL) 9367727 211
SP-D (ng/mL) 2667182 25
BAL parameters
Total cells 105mL1 4.573.5 1.
Macrophages (%) 96.574.1 86.
Lymphocytes (%) 2.571.8 9.
Neutrophils (%) 0.670.9 1.
Eosinophils (%) 0.570.7 1.
Ratio of CD4/CD8 2.272.3 1.
Data are presented as no or mean7SD.
po0.05 compared with idiopathic NSIP and CVD-NSIP.
ypo0.05 compared with IPF/UIP and CVD-UIP.the cut-off value of AECA. These individuals did not show
any clinical, radiological or serological evidence of pulmon-
ary disease or CVD.Expression of AECA in sera
In the control group, the ER value (mean7SD) of AECA was
0.24670.101. There was no significant difference in the ER
with regard to gender, age and smoking habits. The cut-off
value of AECA was determined to be 0.549 using Rosenberg’s
method.6–8,11,15,16
With this cut-off value, 5 of the 20 patients with IIP (25%)
and 9 of the 24 patients with CVD-ILD (37.5%) were positive
for AECA. Compared with control levels, the prevalence and
ER values of AECA were significantly increased in both IIP
patients and CVD-ILD patients. No significant difference was
found in the ER between patients with IIPs and those with
CVD-ILD (0.59770.259 and 0.47670.178, respectively)
(Figure 1). Next, we compared the expression of AECA
among the histologic subgroups UIP and NSIP. Interestingly,
all of the sera from patients with IPF/UIP tested negative for
AECA, whereas the samples from 5 out of 10 patients with
idiopathic NSIP (50%) were positive, indicating that the
prevalence of AECA was significantly higher in cases of
idiopathic NSIP than in cases of IPF/UIP. Among patients with
idiopathic NSIP, 1 out of 2 patients with cellular NSIP and 4
out of 8 patients with fibrosing NSIP were positive for AECA.
In CVD-ILD, 5 out of 14 patients with CVD-UIP (35.7%) and 4
out of 10 patients with CVD-NSIP (40%) were found to be
positive. As shown in Figure 2, the ER value of AECA was
significantly lower in patients with IPF/UIP than those withCVD–associated ILD
pathic NSIP CVD-UIP CVD-NSIP
14 10
679.2 60.777.5 54.579.7
(30) 10 (71) 4 (40)
(40) 10 (71) 4 (40)
370.7 2.370.8 2.270.8
6717.5 75.4720.6 72.8719.9
978.5 79.9720.6 82.679.2
5759 238773 2777183
57306 17057514 18457460
271699 100471203 9697520
37129 2607328 2417180
970.6 2.971.9 2.471.5
4712.2 87.7713.6 75.4728.3
2710.3 5.273.8 16.1721.2y
071.4 6.971.4 1.572.4
372.5 1.371.1 1.171.8
571.5 2.372.6 1.470.9
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Figure 1 ER value of AECA in patients with IIPs, CVD–asso-
ciated ILD and the control group. The dotted line represents the
cut-off value. Horizontal lines, boxes, error bars and circles
represent the median, 25th and 75th percentile, 10th and 90th
percentile, and data apart from 10th or 90th percentile,
respectively. AECA, anti-endothelial cell antibodies; ER, ELISA
ratio. *po0.0001.
Figure 2 ER value of AECA in patients in each subgroup. The
dotted line represents the cut-off value. Specifics of the box
plot are as described in Figure 1. AECA, anti-endothelial cell
antibodies; ER, ELISA ratio. *po0.01, ypo0.05.
AECA in interstitial lung disease 131idiopathic NSIP, CVD-UIP or CVD-NSIP (po0.05). Among
patients with idiopathic NSIP, CVD-NSIP and CVD-UIP, the
prevalence and ER values of AECA were not significantly
different. In cases of CVD-ILD, the ER value and prevalence
was not significantly different among the four underlying
CVDs (data not shown).Relationship between AECA levels and clinical
parameters
The ER values of AECA in sera did not correlate with
pulmonary function, laboratory parameters including serumlevels of KL6, SP-D and other autoimmuno-antibodies, or the
differential fraction of alveolar cells (Figure 3). Even among
IIP patients only, ER values were not related to these
findings. Of the IPF/UIP patients who tested negative for
AECA, 5 died of respiratory failure. Among the idiopathic
NSIP patients, 1 AECA-negative individual did not respond to
corticosteroids and died of respiratory failure. Among the
CVD-NSIP patients, 1 AECA-positive individual with SSc, who
did not receive therapy because his respiratory condition
was stable, died of renal crisis. Collectively, among our
cases, there was no correlation between the presence of
AECA and clinical features such as responsiveness to
treatment and prognosis.Discussion
The present study investigated the expression and clinical
significance of AECA in patients with IIPs compared with
those with CVD-ILD. We found a significant difference in the
prevalence and ER values of AECA among the histologic
subgroups of IIPs. One half of all idiopathic NSIP patients had
AECA, while none of the IPF/UIP patients did. In addition,
the ER values of AECA were significantly higher in cases of
idiopathic NSIP than in cases of IPF/UIP. By contrast, among
patients with CVD-ILD, no difference was found in the
prevalence or ER values of AECA, which were similar to
those in cases of idiopathic NSIP, between patients with
CVD-UIP and those with CVD-NSIP. There was no significant
relationship between the expression of AECA and clinical or
laboratory findings.
IIPs have been classified into subgroups, each with a
distinct histologic pattern and prognosis. It has been
suggested that each subgroup has a different pathologic
process. In this context, it is interesting that AECA were only
found in idiopathic NSIP patients (50%), and not IPF/UIP
patients (0%). Although the precise role of AECA in ILD
remains unclear, the variation in the expression of AECA
among the histologic subgroups of IIPs may be associated
with a distinct pathogenesis. Recently, Fujita et al.23
suggested that certain cases of idiopathic NSIP could be
considered identical to CVD-NSIP, because the clinical
characteristics were quite similar despite the presence of
underlying CVD. Consistent with this, our previous study
showed that in terms of prognosis and responsiveness to
therapy, idiopathic NSIP was similar to CVD-NSIP.24 Interest-
ingly, the present study revealed the prevalence and ER
values of AECA in patients with idiopathic NSIP to be
comparable to those in patients with CVD-UIP and CVD-NSIP.
In terms of the expression of AECA, idiopathic NSIP was more
similar to CVD-ILD than IPF/UIP. As idiopathic NSIP is a
provisional category that requires further elucidation and
definition as described in the ATS/ERS statement,17 this
antibody might be used to account for a part of this entity.
We evaluated the relationship between AECA expression
and pulmonary function and laboratory findings, such as KL-6
levels and SP-D values. Impaired lung function, shown by a
decreased FVC and low PaO2 value in cases of ILD, is
considered to reflect disease severity.25 KL-6 is mainly
expressed on type II pneumocytes and respiratory epithelial
cells, and serves as a useful clinical marker that reflects the
disease activity of ILD.26 SP-D, a lung-specific protein, is also
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Figure 3 Association of AECA and the findings concerned with ILDs. AECA, anti-endothelial cell antibodies; ER, ELISA ratio; BAL,
bronchoalveolar lavage.
T. Matsui et al.132considered to be a useful marker of ILD.27 In the present
study, no relation was found between the ER values of AECA
and these parameters. We also evaluated the relationship in
patients with IIP only to exclude the influence of underlying
CVD. However, there was no significant correlation among
these parameters. Thus, AECA cannot be used as a serum
marker that represents disease activity or severity.
ILDs are characterized by damage to the lung parenchyma
with varying patterns of inflammation and fibrosis, which
mainly target alveolar epithelial cells.17,28,29 In addition to
these epithelial cell changes, it was recently reported that
vascular damage is also present in patients with ILDs.18,30
Takabatake et al.18 demonstrated pulmonary endothelial
cell injury in ILD patients by assessing the kinetics of 123I-
metaiodobenzylguanidine (123I-MIGB). In patients with ILDs,
the rate at which 123I-MIBG was washed out from the lungs,
which reflects pulmonary endothelial cell injury, was
reduced compared with that in normal controls. Moreover,
the washout rate was correlated with parameters for
disease severity. In Takabatake’s study, however, it is not
clear whether the degree of endothelial cell injury differed
among histologic subgroups of ILD, because a pathologic
diagnosis by surgical lung biopsy was not done. Based on the
results of the present study, the expression of AECA may be
attributable, in part, to the endothelial cell injury observed
in ILD, especially idiopathic NSIP and CVD-ILD. On the other
hand, a recent study reported that levels of vascular
endothelial growth factor (VEGF) were decreased in BAL
fluids in patients with IIPs and CVD-ILDs.30 The reduction in
VEGF, which plays a multifunctional role in the maintenance
of vascular structure and function, induces apoptosis of
endothelial cells, leading to damage to the microcapillary
endothelium. Taken together, these findings suggest that
injury to the endothelial cells contributes in part to thepathological changes in patients with ILDs, and that AECA
might be related to this process.
Recently, Margo et al.31 indicated the presence of AECA in
IPF patients. In contrast to our study, 12 sera from 18
patients reacted with HUVEC. We suppose some reasons for
this discrepancy. One is that they used an indirect immuno-
fluorescence technique to detect AECA. Another reason is
that the targeted patients differed greatly. They contained
cases of pulmonary hemorrhage and lung transplantation.
Moreover, all biopsies showed morphologic evidence of
microvascular injury, which suggested ILDs associated with
vasculitis rather than idiopathic ILDs. In this study, we
included biopsy-proven IPF and idiopathic NSIP patients
and excluded patients with apparent vasculitis. Studies
of ILDs sometimes cause confusion, because intended
patients differ from study to study. We need further studies
in a larger cohort of biopsy-proven, selected idiopathic
patients to improve our understanding of the role of
AECA in IIPs.
In conclusion, among IIP patients, we detected AECA only
in those with idiopathic NSIP, not those with IPF/UIP, and the
prevalence and ER values of AECA in cases of idiopathic
NSIP were similar to those in cases of CVD-ILD. Although the
role of AECA in ILD remains unclear, this difference in
expression level between IPF/UIP patients and idiopathic
NSIP patients might be associated with different pathologic
processes. In addition, it is suggested that idiopathic
NSIP is more similar to CVD-ILD than IPF/UIP in terms of
AECA expression. These results may provide important
knowledge that contributes to a better understanding of
the distinct pathophysiology of each form of IIPs. Further
studies will elucidate the characteristics of the antigen
recognized by AECA and its precise role in the pathophysiol-
ogy of ILDs.
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